Roche Signs Exclusive Agreement with IT-IS Life Sciences
News May 30, 2011
Roche Applied Science has signed a worldwide exclusive OEM agreement with IT-IS Life Sciences Ltd for the distribution of the new LightCycler® Nano Instrument, which will complete the company´s portfolio for the low throughput real-time PCR systems market (32-well format, 4x 8-tube strips).
Market availability of the new system is planned for mid 2011. Financial details of the agreement were not disclosed.
For more than 10 years, Roche has repeatedly set the standard for real-time PCR competence with the LightCycler® Instrument series and its broad capabilities for RT-PCR assays, analysis software and reagents.
The technology is widely used in nucleic acid quantification, gene expression profiling, and detecting genetic variations.
The new LightCycler® Nano Instrument is a 32-well format real-time PCR cycler with functionality and easy-to-use software. Silent and compact, this instrument will be the perfect bench-top companion for laboratory end users performing real-time PCR on a daily basis.
The system uses convenient, standard PCR strips and can support all common detection dyes with its full spectrum optics.
“With the LightCycler® Nano Instrument, we now provide a very compact and innovative high performance PCR instrument under a worldwide exclusive agreement”, according to Gerd Haberhausen, Life Cycle Leader qPCR and NA Purification of Roche Applied Science.
Haberhausen continued, “The new LightCycler® Nano Instrument delivers proven high quality at an affordable price and expands our qPCR business into a new segment. Customers will love the smart design of the instrument and appreciate the high quality data they can produce with it.”
“We believe that the creative engineering capability of IT-IS and the market leadership position of Roche in real-time PCR are a perfect match for each other. The LightCycler® Nano system will deliver exceptional performance, ease of use, and value due to its highly integrated solid-state design.” said Roderic Fuerst, CEO of IT-IS Life Sciences Ltd.